Actively Recruiting
National, Non Interventional Study of Invasive Pneumococcal Disease in Children and Newborns
Led by Association Clinique Thérapeutique Infantile du val de Marne · Updated on 2026-04-28
2500
Participants Needed
1
Research Sites
994 weeks
Total Duration
On this page
Sponsors
A
Association Clinique Thérapeutique Infantile du val de Marne
Lead Sponsor
P
Pfizer
Collaborating Sponsor
AI-Summary
What this Trial Is About
After 7 then 13 valent pneumococcal conjugate vaccine (PCV) implementation in France in children, we will evaluate the impact of this vaccination on invasive pneumococcal disease (IPD). We will describe the clinical characteristics of IPD, pneumococcus serotyping, underlying conditions and vaccination status.
CONDITIONS
Official Title
National, Non Interventional Study of Invasive Pneumococcal Disease in Children and Newborns
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Isolate of Streptococcus pneumoniae from at least one blood culture, pleural fluid, joint fluid, cerebrospinal fluid, or other normally sterile body site, or a positive blood PCR
You will not qualify if you...
- Pneumococcal strain not transmitted to National Reference Center for Pneumococci or to Regional Pneumococci Observatory
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
ACTIV
Créteil, France, 94000
Actively Recruiting
Research Team
L
Levy Corinne
CONTACT
B
Bechet Stephane
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here